Breast Cancer News and Research

Latest Breast Cancer News and Research

Cyclin D1 oncogene may promote chromosomal instability

A team of researchers at Jefferson's Kimmel Cancer Center (KCC) led by Richard G. Pestell, M.D., PhD., FACP, Director of the KCC and Chair of the Department of Cancer Biology, have shown in a study published online Feb. 6 in the Journal of Clinical Investigation that the oncogene cyclin D1 may promote a genetic breakdown known as chromosomal instability (CIN). CIN is a known, yet poorly understood culprit in tumor progression.

7 Feb 2012

Komen Foundation works to regain balance in the wake of Planned Parenthood funding flap

News outlets parse different angles of this story -- which broke last week -- including how the Web and social media affected it and how Komen is working to rebuild its donor list.

7 Feb 2012

Researchers reveal how molecular imaging can solve breast cancer mysteries

In two new studies featured in the February issue of the Journal of Nuclear Medicine, researchers are revealing how molecular imaging can be used to solve mysteries about difficult cases of breast cancer.

7 Feb 2012

Genomic Health plans to establish wholly owned subsidiary

Genomic Health, Inc. today announced plans to establish a wholly owned subsidiary with the goal of improving the quality of diagnosis, communication and support for millions of patients and their families faced with common and rare genetic conditions.

7 Feb 2012

Viewpoints: Komen's retreat; Romney's selected support of Medicare cuts; Heritage refuses blame for individual mandate

A group like Komen only has the quality service it provides and goodwill garnered over the years to encourage donations and support. Its trademark pink is not as bold as before. For the moment, it seems drab and faded.

6 Feb 2012

Even minimal regular alcohol could harm health say experts

Television adverts are introduced to carry home the message that drinking just a little over the daily recommended alcohol limit can lead to serious health problems. Current medical advice states that men should drink a maximum of four units a day, with women advised to consume no more than three.

6 Feb 2012

Body's zinc control mechanisms may be key to aggressive breast cancer treatments

The body's control mechanisms for delivering zinc to cells could be key to improving treatment for some types of aggressive breast cancer.

6 Feb 2012

First Edition: February 6, 2012

Today's headlines include reports about the continuing fall out from the Obama administration's birth control rule and the latest on the Komen foundation's efforts to bounce back from the Planned Parenthood funding flap.

6 Feb 2012

EntreMed receives $9.3 million in strategic financing

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has received approximately $9.3 million in strategic financing, as previously announced on January 23, 2012.

6 Feb 2012

Komen denies cut in Planned Parenthood funding was political

Komen had said the decision was the result of newly adopted criteria barring grants to organizations under investigation - affecting Planned Parenthood because of an inquiry by a Republican congressman. On Thursday, Komen President Elizabeth Thompson told reporters that the funding decision was unrelated to the investigation into whether Planned Parenthood was illegally using federal funds to pay for abortions.

6 Feb 2012

At local level, Komen affiliates express concern about decision

In California, seven Komen groups ask the national breast cancer group to reverse its funding decision. Others report concerns about community support for future money-raising activities.

6 Feb 2012

Viewpoints: Komen takes a lashing; Is the safety net really intact?; Romney assails HHS' rule on contraception

With its roster of corporate sponsors and the pink ribbons that lend a halo to almost any kind of product you can think of, the Susan G. Komen for the Cure foundation has a longstanding reputation as a staunch protector of women's health. That reputation suffered a grievous, perhaps mortal, wound this week from the news that Komen, the world's largest breast cancer organization, decided to betray that mission.

5 Feb 2012

Komen Foundation seeks to restore public support after ending cuts to Planned Parenthood

The prominent breast cancer charity announced Friday in a blog post that it had reversed this decision, which had stirred an outcry.

5 Feb 2012

Road Hockey To Conquer Cancer to kick off sophomore campaign on Feb. 7

It's an ordinary workday, and the lunch hour at Commerce Court is bustling with people. Wait a minute! What the heck is going on? Where did those hockey sticks come from? How did those nets appear? There's a road hockey game in progress!! But what the heck is with those guys wearing jockstraps over their suits? After an extraordinary inaugural event that raised $2.4 million for cancer research at The Princess Margaret Cancer Centre and Canadian Cancer Society, Road Hockey To Conquer Cancer will kick off its sophomore campaign with a spontaneous road hockey game on Tuesday, February 7, 2012 at 12:30pm in the courtyard at Commerce Court.

4 Feb 2012

New approach can solve treatment-resistant problem in cancers

Free-flowing cancer cells have been mapped with unprecedented accuracy in the bloodstream of patients with prostate, breast and pancreatic cancer, using a brand new approach, in an attempt to assess and control the disease as it spreads in real time through the body, and solve the problem of predicting response and resistance to therapies.

4 Feb 2012

Soy isoflavone supplements do not reduce breast cancer cell proliferation

Soy isoflavone supplements did not decrease breast cancer cell proliferation in a randomized clinical trial, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

4 Feb 2012

Positive updated results from Aeterna Zentaris' AEZS-108 Phase 1 trial on CRPC

Aeterna Zentaris Inc. today reported positive updated results for the Phase 1 portion of its ongoing Phase 1/2 study in castration- and taxane-resistant prostate cancer (CRPC) with AEZS-108 (zoptarelin doxorubicin), the Company's targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analog.

4 Feb 2012